85 results about "Tumor recurrence" patented technology

The application provides a radionuclide nanohydrogel microneedle and a preparation method and application thereof, and belongs to the field of nanobiomedicine. 32 P-labeled calcium phosphate, which is formed by a biomimetic reaction of Ag2S@Ca 32 P nanoparticles, and a base layer which is a base matrix and comprises hyaluronic acid 32 P nanohydrogel microneedle can release Ag2S nanoparticles in response to a weakly acidic tumor environment, and under the irradiation of near-infrared light, the photothermal conversion efficiency can effectively kill bacteria, effectively improve the tumor hypoxic environment, enhance the treatment effect of radionuclides, play an antibacterial and wound healing promoting role in melanoma defect repair, and maximize the inhibition of tumor growth and tumor recurrence.

The invention relates to the technical field of biomedical engineering and drug delivery, and particularly discloses a novel targeted drug delivery system based on rose fruit extracellular vesicles, which comprises the following steps: preparing rose fruit source extracellular vesicles; preparing a medicine carrying vesicle; preparing targeted modified drug-loaded vesicles; according to the application disclosed by the invention, a stem related pathway is specifically down-regulated through the components of the rose fruits, and meanwhile, conventional tumor cells are killed by using adriamycin, so that a complementary treatment mechanism is formed, and the tumor recurrence risk is fundamentally reduced. The phenylboronic acid group of DSPE-PEG-PBA is used for specifically recognizing sialic acid over-expressed on the surface of a tumor cell, so that the enrichment of the medicine in tumor tissues is remarkably improved, and meanwhile, the distribution of normal tissues is reduced. By means of the natural biocompatibility and low immunogenicity of the RHNVs and in combination with the long circulation characteristic of a PEG chain, the delivery efficiency is guaranteed, the systemic toxicity is reduced to the maximum extent, and particularly the cardiotoxicity and myelosuppression of adriamycin are relieved.

The present disclosure provides compositions and methods for the delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse. The compositions comprise (i) a structure comprising an injectable polymer or scaffold comprising pores; (ii) lymphocytes disposed within the structure, (iii) at least one lymphocyte-adhesion moiety associated with the structure; and (iv) at least one lymphocyte-activating moiety associated with the structure, and optionally an immune stimulant.

The present disclosure relates to chimeric antigen receptor cells targeting ROBO1, in particular, enhanced CAR-T cells and CAR-NK cells targeting ROBO1, and preparation and application thereof. The cells can stably expressing CAR elements, while secreting extracellular domain molecules expressing PD-1 protein or mutants thereof, and thus may block PD-11PD-L1 molecular interaction. It has been found through animal experiments that the cells have very good anti-tumor effects, and the above-mentioned cells can significantly reduce tumor recurrence and improve the survival rate compared with the conventional ROBO1-targeted CAR modified cells.

The invention provides a tumor radiotherapy rehabilitation abnormity early warning method and system, and relates to the technical field of medical data analysis, and the method comprises the steps: obtaining a first tumor CT image and first image feature information thereof, first focus region detection information and first focus feature information after the first reexamination after tumor radiotherapy treatment; and after the kth review, obtaining a second tumor CT image and second image feature information thereof, and obtaining second focus area detection information and second focus feature information in combination with the first focus feature information so as to determine abnormal early warning information. According to the method and the device, the tumor CT image obtained after each review can be processed by using the anomaly recognition model, and during processing, the tumor CT image obtained during the previous review is combined for comprehensive analysis, and the condition and change of a focus can be analyzed, so that the comprehensiveness and the accuracy of analysis are improved, the distinguishing accuracy of pseudomorphism and tumor recurrence is improved, and the success rate of tumor review is improved. And the early warning accuracy is improved.

This invention relates to the field of biotechnology, specifically to a TruC-T cell that secretes and expresses IL-7 and PF4 to enhance anti-tumor activity and targets uPAR, and its application. Interleukin-7 (IL-7) can effectively promote the development, survival, and proliferation of T cells, while platelet factor 4 (PF4 / CXCL4) can regulate the immune response and chemotactically attract leukocytes to specific sites; the synergistic effect of the two can enhance the anti-tumor function and persistence of T cells. Meanwhile, urokinase-type plasminogen activator receptor (uPAR) is highly expressed in various solid tumors and hematological malignancies, making it an ideal target for tumor therapy; TruC-T cells targeting uPAR can precisely act on tumor tissue, and combined with the immune-enhancing effects of IL-7 and PF4, can significantly improve the efficacy of anti-tumor immune responses, prolong the duration of therapeutic effects, and reduce tumor recurrence.

The application discloses a novel AIE photosensitizer and a preparation method and application thereof. The AIE photosensitizer of the application comprises TDQ shown in the following structural formula, has superior photo-thermal conversion performance and photodynamic performance, and can be used for preparing a tumor diagnosis reagent or a tumor treatment drug. The co-loading liposome of TDQ and a senescence-inducing molecule (Ali) can be used as a multi-modal light diagnosis and treatment agent to realize efficient delivery of drugs to tumor tissues, and the photo-thermal therapy and the photodynamic therapy based on TDQ not only induce cell apoptosis through oxidative stress and mitochondrial dysfunction, but also trigger cancer cell senescence and promote the secretion of SASPs, so that the anti-tumor immunity is significantly enhanced, and finally the growth of primary tumors, tumor recurrence and re-metastasis are inhibited. The material of the application has simple preparation process, low cost, and is suitable for scale production and clinical medical use.

The invention belongs to the technical field of biological medicine, and particularly relates to application of an anti-HIV drug in inhibition of non-small cell lung cancer drug resistance. The invention finds that the combined use of the anti-HIV drug and EGFR-TKI can effectively and specifically target the MRD drug-resistant cells, inhibit the formation of the MRD drug-resistant cells, significantly improve the curative effect of EGFR-TKI and delay tumor recurrence.

The present invention relates to an oncolytic adenovirus capable of co-expressing interleukin-12 and a C-met-inhibiting oligonucleotide; and an antitumor immune-boosting composition and anticancer composition comprising the oncolytic adenovirus. The present invention has first identified an adenovirus system having simultaneous effects of IL-12 expression and C-met inhibition in cancer gene treatment. The adenovirus system of the present invention is capable of inhibiting C-met while expressing interleukin-12, thereby restoring immune functions in a tumor environment to enhance anticancer effects such as the inhibition of tumor recurrence and tumor growth and to inhibit tumor migration. Accordingly, the adenovirus system of the present invention can be effectively used in the treatment of cancer.

The present disclosure provides compositions and methods for the delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse. The compositions comprise (i) a structure comprising an injectable polymer or scaffold comprising pores; (ii) lymphocytes disposed within the structure, (iii) at least one lymphocyte-adhesion moiety associated with the structure; and (iv) at least one lymphocyte-activating moiety associated with the structure, and optionally an immune stimulant.

The application belongs to the technical field of biomedical materials, and discloses a acutine-chitosan / calcium carbonate hemostatic sponge as well as a preparation method and application thereof. The acutine and chitosan are condensed to obtain acutine-chitosan, and then the acutine-chitosan is reacted with sodium carbonate, calcium hydroxide and urea to form the acutine-chitosan / calcium carbonate hemostatic sponge. In-vivo and in-vitro experiments verify that the sponge can be used for hemostasis and antibiosis, and due to the pH sensitivity of the acutine-chitosan, the acutine can be intelligently controlled to be released under acidic conditions (cancer acidic environment), so that the sponge can be used for rapid hemostasis during cancer surgery, and also helps to prevent recurrence of liver cancer after surgery. Therefore, the multifunctional acutine-chitosan / calcium carbonate hemostatic sponge of the application provides a 'one-stop' synergistic strategy for intraoperative hemostasis and postoperative prevention of tumor recurrence of liver cancer, and has great clinical application potential.

The application provides a magnetic response composite hydrogel for integrated repair of bone defects and a preparation method thereof, and belongs to the technical field of medical materials. The composite hydrogel can efficiently inhibit tumor cell activity under the time sequence regulation of an external alternating magnetic field, and then provide a suitable microenvironment and key components for bone tissue regeneration, so that signal conversion and function connection from tumor killing to bone repair are realized. The material has good injectability and self-healing ability, can minimally invasively fill irregular defects, and has significant advantages in simplifying the clinical treatment procedure, shortening the treatment course, reducing the risk of tumor recurrence and improving the repair quality, and provides a new and integrated treatment strategy for tumor-related bone defects.

The invention provides a personalized cancer vaccine based on apoptosis vesicles and a preparation method and application thereof, and belongs to the technical field of biological medicine, the personalized cancer vaccine comprises apoptosis vesicles, an immunologic stimulant and a biocompatibility carrier; the apoptosis vesicles are extracellular vesicles generated after tumor cells are subjected to apoptosis induction; the biocompatible carrier is a modified chitosan hydrogel, and the biocompatible carrier is a modified chitosan hydrogel; the immunologic stimulant is loaded in the apoptosis vesicle, and the apoptosis vesicle loaded with the immunologic stimulant is embedded into the modified chitosan hydrogel. According to the invention, apoptosis vesicles generated by induction of tumor cells of a patient are taken as a core, the apoptosis vesicles have a natural tumor antigen library and a strong immune activation capability, and personalized precise treatment can be realized; meanwhile, the invention provides a preparation method and application in postoperative tumor recurrence prevention and treatment, and provides technical support for clinical transformation.

The application belongs to the technical field of cell engineering, and particularly relates to a bispecific antibody targeting CD22 and CD19, a chimeric antigen receptor thereof and application. In the bispecific antibody, a CD22 light chain and a CD22 heavy chain are connected through a linker 4 to form a CD22 single-chain antibody, and a CD19 light chain and a CD19 heavy chain are connected through a linker 4 to form a CD19 single-chain antibody, which comprises one of the following structures: (1) the CD22 single-chain antibody and the CD19 single-chain antibody are connected through a linker 1 or a liner 2; (2) the two ends of the CD19 single-chain antibody are connected with the CD22 light chain and the CD22 heavy chain through a linker 3, respectively. The chimeric antigen receptor provided by the application can simultaneously target two different tumor antigens, improve the killing of tumor cells, reduce the probability of immune escape, and reduce the tumor recurrence rate after CAR-T treatment.

The invention discloses an FGF2 inhibitor composition of a targeted iCAFs subgroup and application of the FGF2 inhibitor composition in bladder cancer prevention and treatment, and relates to the technical field of FGF2 inhibitor compositions of targeted iCAFs subgroups, the FGF2 inhibitor composition is used for preparing a medicine for bladder cancer prevention and treatment, the composition comprises an FGF2 inhibitor, and the FGF2 inhibitor can inhibit the bladder cancer by inhibiting interaction between FGF2 secreted by ICAM1 + iCAFs and tumor stem cell surface CD44, so that the bladder cancer can be prevented and treated, and the bladder cancer can be prevented and treated. According to the application disclosed by the invention, ICAM1 + inflammatory cancer related fibroblast iCAFs subpopulation in a bladder cancer recurrence related tumor microenvironment is targeted, a fibroblast growth factor FGF2 signal secreted by the ICAM1 + inflammatory cancer related fibroblast iCAFs subpopulation is specifically inhibited, the dependency support of the tumor microenvironment on the stemness maintenance of the tumor stem cells is destroyed, and the stemness maintenance of the recurrence related tumor stem cell subpopulation is inhibited. Therefore, the biological basis of tumor recurrence and progression is weakened from the source.

The invention belongs to the technical field of biological medicine, and particularly relates to a co-load bionic whole-tumor vaccine as well as a preparation method and application thereof. The preparation method comprises the following steps: preparing fungal cell wall nanoparticles, preparing dead tumor cells and synthesizing the coupled vaccine. The invention discloses a co-load bionic whole-tumor vaccine, which breaks through the expression limitation of natural antigens, and enhances an immunogenicity activation signal through artificial modification. Immune cells are activated in a targeted manner through fungal cell wall components, so that the antigen presentation efficiency is remarkably improved. The compound can be applied to preparation of medicines for preventing and treating tumor diseases or medicines for inhibiting tumor recurrence or metastasis. The invention also discloses a preparation method of the co-loaded bionic whole-tumor vaccine, the preparation process is simplified, and the process complexity is reduced by using a standardized coupling technology of microorganisms and tumor cells.

The application belongs to the technical field of drug delivery carrier, and particularly relates to a dual-metal nanodot-oncolytic virus intravenous delivery system and a preparation method and application thereof in tumor immunotherapy. The oncolytic adenovirus is used as raw material, and the dual-metal nanodot-adenovirus chimera is constructed by using the covalent force of 4-maleimide butyric acid-N-succinimidyl ester. The preparation performance, cytotoxicity, action mechanism, in-vivo anti-tumor effect, anti-tumor immunity, anti-tumor recurrence and anti-tumor metastasis effect of the chimera are evaluated. The preparation process is simple, the prepared dual-metal nanodot-adenovirus chimera has small and uniform particle size, is conducive to enrichment in tumor tissues through the enhanced permeability and retention (EPR) effect, has high drug loading capacity, good safety and can generate high-intensity MRI signals at the tumor site. The designed dual-metal nanodot-adenovirus chimera realizes the integration of tumor diagnosis and treatment.

A wearable device (1) for treating cancer cells by mechanical stimulation of a patient's surface tissue, in particular skin, subcutaneous tissue or mammary gland, wherein the device (1) comprises: a support element (2) applicable to the patient's tissue; and stimulation and control means (3) connected to the support element (2) wherein the stimulation and control means (3) comprise: at least one actuator (4) for delivering the mechanical stimulation at at least one stimulation point (5); at least one sensor (6) for detecting a physical property at the tissue of the patient to be treated and for generating a corresponding sensor signal; and a control unit (7) connected to the actuator (4) and to the sensor (6), the control unit (7) for regulating the movement of the actuator (4) by a control signal in dependence on said at least one sensor signal, in which the mechanical stimulation is transmitted by the actuator (4) to the stimulation point (5) in order to deform the tissue to be treated in dependence on a periodic trend, especially the contraction and relaxation of the tissue.

The invention discloses a traditional Chinese medicine composition for treating tumors caused by internal stagnation of toxic blood stasis. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 47-49 parts of longpimpinella pedicularis, 24-26 parts of black ants and 24-26 parts of toad skin. According to the invention, only the three medicinal materials, namely Longdiland, black ant and toad skin, are adopted, the formula is simple, the medicinal materials are wide in source and controllable in cost, the pharmacological actions of the three medicinal materials are complementary, Longdiland enhances immunity and resists inflammation, black ant regulates immunity, resists inflammation and relieves pain, toad skin directly plays an anti-tumor role, the effects of attacking hard mass, breaking stasis, resisting cancer and diminishing swelling are realized, and a precise formula is prepared aiming at the pathogenesis of internal stagnation of toxic blood stasis; clinical verifications prove that the traditional Chinese medicine can effectively relieve clinical symptoms of tumors caused by internal accumulation of toxic stasis and control recurrence and metastasis of the tumors; meanwhile, the body immunity of patients is improved, the life quality is improved, the survival time is prolonged, and compared with existing partial traditional Chinese medicine preparations, the curative effect is clearer, and the pertinence is higher. The invention further discloses a preparation method of the traditional Chinese medicine composition.

The invention discloses a preparation method and application of an iron-copper diatomic nano-enzyme, and relates to a preparation method and application of a nano-enzyme. The invention aims to solve the problem that the clinical application of the traditional treatment means is often limited and challenged by severe systemic toxicity, drug resistance and tumor recurrence although the traditional treatment means improve the survival rate of patients. The method comprises the following steps: 1, dissolving dimethylimidazole in absolute methanol, and stirring to obtain a solution A; step 2, dissolving zinc nitrate hexahydrate, ferric ammonium citrate and copper acetylacetonate in absolute methanol, and stirring to obtain a solution B; 3, mixing and stirring the solution A and the solution B, centrifuging, washing and drying to obtain a white sample ZIF-8; and step 4, pyrolyzing the white sample ZIF-8 at 900 DEG C to obtain black powder, namely the iron-copper diatomic nano-enzyme. The invention belongs to the technical field of active oxygen mediated tumor treatment.

The invention discloses a malignant tumor postoperative washing agent as well as a preparation method and application thereof. The method comprises the following steps: taking hematoxylon decoction pieces, adding water, heating, refluxing and extracting to obtain an extracting solution, filtering the extracting solution, and concentrating filtrate to obtain a concentrated solution; adding ethanol into the concentrated solution, standing and precipitating, and carrying out suction filtration or centrifugation to obtain a first supernatant; recovering ethanol in the first supernatant under reduced pressure to obtain a sappan wood water extract liquid medicine; supplementing water into the hematoxylon water extract liquid medicine, and adjusting the liquid medicine ratio to a preset value; adding an antioxidant, stirring and dissolving, standing, and filtering to obtain a second supernatant; adding water into the second supernatant, and adjusting the liquid medicine ratio to a preset value; and then adding an excipient, and stirring for dissolving. The malignant tumor postoperative washing agent with the sappan wood extract as the active ingredient is used for local washing of surgical wounds, shows a killing effect on various cancer cells, and can effectively remove residual tumor cells, so that postoperative recurrence and metastasis of tumors are prevented.

The application discloses a tumor stem cell inhibiting medicine based on gene regulation and a preparation method thereof, and belongs to the technical field of biological medicines. The medicine takes a targeted interference fragment of a tumor stem cell specific regulation gene TSC-G as a core active component, and is composed of only the targeted interference fragment and a modified liposome. The modified liposome is composed of DSPC, Chol and PEG-DSPE in a specific ratio, and has high targeting property and good stability. The preparation method comprises four steps of targeted interference fragment synthesis, modified liposome preparation, medicine assembly and purification, and has simple process and high purity. The medicine can effectively inhibit self-renewal, proliferation and differentiation of tumor stem cells, the tumor stem cell inhibition rate is greater than or equal to 88%, the tumor volume inhibition rate in vivo is greater than or equal to 78%, the medicine has no toxicity to normal body cells, the technical scheme is unique, the medicine can be used for clinical tumor treatment, and the problem of tumor recurrence and drug resistance can be solved from the root.

Provided is a cytokine combination useful for treating a tumor and / or preventing recurrence or metastasis of the tumor. The cytokine combination with at least three cytokines selected from the following groups: interleukin 12 (IL12) or a functional variant thereof, granulocyte-macrophage colony-stimulating factor (GMCSF) or a functional variant thereof, FMS-like tyrosine kinase 3 ligand (FLT3L) or a functional variant thereof, interleukin 2 (IL2) or a functional variant thereof, interleukin 15 (IL15) or a functional variant thereof, interleukin 21 (IL21) or a functional variant thereof, and interleukin 7 (IL7) or a functional variant thereof. Also provided is a nucleic acid molecule encoding the cytokine combination and a vector thereof, a cell, a pharmaceutical composition, and a application thereof for the manufacture of a drug for treating the tumor and / or preventing recurrence or metastasis of the tumor.

This invention discloses a bone repair scaffold system for tumor early warning and non-invasive treatment, comprising a bone repair scaffold, a microenvironment monitoring RFID module, a controlled drug release module, a signal reading system, and a cloud processor. The bone repair scaffold is shaped to fit the wound site and has a porous internal structure. The microenvironment monitoring RFID module is disposed on the internal and external surfaces of the bone repair scaffold. The controlled drug release module includes a microwave induction module and a drug storage unit. An external microwave excitation causes the microwave induction module to heat up, stimulating the thermoresponsive drug storage unit to release the drug. The signal reading system communicates with the microenvironment monitoring RFID module via radio frequency and is interconnected with the cloud processor via the internet. This invention can promote bone repair while rapidly monitoring tumor recurrence, alerting patients to seek medical attention early. Simultaneously, the drug release module enables non-invasive treatment, reducing patient suffering, improving quality of life, and prolonging survival.

This invention discloses a nanoengineered bacteria-hydrogel composite formulation for local treatment of postoperative pancreatic ductal adenocarcinoma, its preparation method, and its application. The preparation method includes adding a tetrahydrofuran solution containing DSPE-PEG-NH2 to a mixture of THF-H2O and rotary evaporating to obtain NPs-N; mixing the obtained Bt bacterial suspension with a 2-iminothiacyclopentane solution to obtain Bt-SH; co-incubating Bt-SH and NPs-N to obtain NPs-N@Bt, and then adding it to a GelMA solution to form a gel. This nanoengineered bacteria-hydrogel composite formulation can spontaneously form a digestive enzyme protein crown in the postoperative microenvironment, promoting bacterial penetration and preventing pancreatic fistula. After the bacteria degrade deep-seated mucin, they release mucin from the tumor microenvironment, restoring the sensitivity of PDAC tumors to digestive enzymes and effectively controlling tumor recurrence and metastasis.

The invention belongs to the field of medicines, and discloses application of macastine B in preparation of anti-inflammatory, repair-promoting and relapse and metastasis-resisting medicines after liver cancer operation. The invention discloses an application of macastine B in preparation of a medicine for recovering a liver cancer patient after partial liver resection. The macaxantin B can promote liver function recovery, reduce the level of inflammatory factors of liver tissues and serum species, and reduce the tumor recurrence rate and the tumor visceral metastasis rate after tumor excision after an orthotopic liver cancer surgical operation, and compared with simultaneous administration of a liver protection drug and an anti-tumor drug, the macaxantin B has the advantages that the liver metabolism burden is reduced, and the curative effect is improved. And a novel drug treatment choice is provided for disease management of a liver cancer patient in a perioperative period. The invention discloses a medicine for promoting postoperative recovery of an orthotopic liver cancer surgical operation. The medicine comprises an effective therapeutic dose of macastine B and pharmaceutically acceptable auxiliary materials.

This application relates to enhancers of T cells or B cells with memory function, inhibitors of malignant tumor recurrence, and inducers of memory function in T cells or B cells. The object of this invention is to provide enhancers of endogenous T cells or B cells with memory function and inhibitors of malignant tumor recurrence for long-term, sustained rejection of malignant tumors. Enhancers of T cells or B cells with memory function in the recipient, and inducers of memory function in T cells or B cells in the recipient, are prepared, wherein the enhancers and inducers comprise a nucleic acid delivery medium, a nucleic acid encoding interleukin-7 (IL-7), and a nucleic acid encoding chemokine (C-C motif) ligand 19 (CCL19). Additionally, an inhibitor of malignant tumor recurrence is prepared, comprising a nucleic acid delivery medium, a nucleic acid encoding interleukin-7 (IL-7), and a nucleic acid encoding CCL19.

The invention provides a combined preparation for treating nasopharynx cancer and a preparation method and application thereof, and belongs to the technical field of tumor cell immunotherapy, the combined preparation comprises rAdp53-DCT cells and rAd-P53 adenoviruses which are independently packaged; the quantity ratio of DC cells to CIK cells in the rAdp53-DCT cells is 1: (10 to 100). The rAdp53-DCT cell provided by the invention can enhance the immune system function of a body and improve the immune monitoring and killing ability of the body to tumor cells; the rAd-P53 adenovirus can directly induce tumor cell apoptosis, and the rAd-P53 adenovirus and the rAd-P53 adenovirus are combined for application, so that the anti-tumor effect can be achieved from different mechanisms, the tumor treatment effect is remarkably improved, and the tumor recurrence rate is reduced.

The present application provides a modified dual-targeting T cell receptor complex and immune cells modified thereby. It also provides the nucleic acid molecules encoding the modified dual-targeting T cell receptor complex, the vectors comprising the nucleic acid molecules, the host cells or immune cells comprising the vectors, the methods for preparing the immune cells, the pharmaceutical compositions comprising the modified dual-targeting T cell receptor complex, nucleic acid molecules, vectors, host cells or immune cells, as well as the use of the modified dual-targeting T cell receptor complex, nucleic acid molecules, vectors, host cells, immune cells and / or pharmaceutical compositions in the preparation of the drugs for prevention and / or treatment and / or adjunctive treatment of cancer, delaying cancer progression, and reducing and / or inhibiting tumor recurrence.